Skip to main contentAI and Advanced
/
IPCALAB · NSEMarket ticker unavailable · configure an authorised index feed
IP
NSE · Equity shares · Biotechnology & Drugs-2.80 · -0.14%
IPCA Laboratories IPCALAB
NSE:INR 1,936.1
BSE:INR 1,729.8
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for IPCALAB
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,938.9
Day rangeINR 1,905 — INR 1,983
52-week rangeINR 1,251.6 — INR 2,001.5
Volume3.37 L
Market cap43,877.97
P/E35.6
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)9,646.33
Net Income (INR Cr)1,141.12
Rev Growth (5 Year %)12.22
EPS Growth (5 Year %)-0.01
P/E Ratio35.6
Book Value310.06
EPS46.82
Price/BV6.24Computed
Research path: Interpret IPCA Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
IPCALABIPCA Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 12,370.19 | 11,760.55 | 11,101.28 |
| Accumulated Depreciation Total | -2,892.15 | -2,574.74 | -2,253.45 |
| Cash Equivalents | 250.65 | 38.83 | 70.12 |
| Other Liabilities Total | 98.33 | 96.95 | 87.83 |
| Accrued Expenses | 342.09 | 294.96 | 361.32 |
| Long Term Debt | 109.12 | 543.24 | 580.41 |
| Common Stock Total | 25.37 | 25.37 | 25.37 |
| Other Equity Total | 9.72 | -19.35 | -2.1 |
| Other Current Assets Total | 14.23 | 11.95 | 24.98 |
| Prepaid Expenses | 62.03 | 57.31 | 48.29 |
| Total Assets | 12,370.19 | 11,760.55 | 11,101.28 |
| Current Portof LT Debt/Capital Leases | 195.26 | 273.35 | 258.78 |
| Additional Paid-In Capital | 96.52 | 96.52 | 96.52 |
| Cash | 186.47 | 128.34 | 138.79 |
| Total Equity | 8,063.81 | 6,948.45 | 6,332.19 |
| Long Term Investments | 223.36 | 216.32 | 303.61 |
| Retained Earnings(Accumulated Deficit) | 7,929.24 | 6,851.93 | 6,218.86 |
| Total Common Shares Outstanding | 25.37 | 25.37 | 25.37 |
| Property/Plant/Equipment Total-Gross | 8,094.55 | 7,260.08 | 6,916.69 |
| Tangible Book Valueper Share Common Eq | 310.06 | 265.87 | 240.4 |
| Goodwill Net | 82.81 | 90.58 | 90.58 |
| Total Liabilities | 4,306.38 | 4,812.1 | 4,769.09 |
| Total Debt | 808.76 | 1,362.74 | 1,438.36 |
| Short Term Investments | 753.4 | 937.88 | 636.44 |
| Cashand Short Term Investments | 1,190.52 | 1,105.05 | 845.35 |
| Total Receivables Net | 2,331.75 | 2,193.32 | 2,108.33 |
| Notes Payable/Short Term Debt | 417.49 | 495.25 | 559.24 |
| Deferred Income Tax | 244.86 | 294.97 | 310.47 |
| Accounts Receivable-Trade Net | 2,017.01 | 1,889.15 | 1,704.38 |
| Property/Plant/Equipment Total-Net | 5,202.4 | 4,685.34 | 4,663.24 |
| Minority Interest | 1,460.25 | 1,439.82 | 1,394.81 |
| Total Current Liabilities | 2,306.93 | 2,386.22 | 2,355.64 |
| Total Inventory | 2,775.08 | 2,599.41 | 2,511.95 |
| Accounts Payable | 940.29 | 846.17 | 776.08 |
| Other Currentliabilities Total | 411.8 | 476.49 | 400.22 |
| Total Long Term Debt | 196.01 | 594.14 | 620.34 |
| Intangibles Net | 114.77 | 112.66 | 142.6 |
| Other Long Term Assets Total | 116.13 | 455.09 | 124.73 |
| Note Receivable-Long Term | 257.11 | 233.52 | 237.62 |
| Unrealized Gain(Loss) | 2.96 | -6.02 | -6.46 |
| Total Current Assets | 6,373.61 | 5,967.04 | 5,538.9 |
| Capital Lease Obligations | 86.89 | 50.9 | 39.93 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.14
Price to Sale Ratio4.55
Growth
Debt 5Yr CAGR %24.96
Margins
Operating Margin 12m15.1
Operating Margin 5y Avg13.44
Net Profit Margin 12m12.35
Net Profit Margin 5y10.14
Yield
Dividend Yield %0.34
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk26.67
Analyst consensus
ConsensusStrong Buy
Consensus score1.64
Analyst opinions14
Strong Sell count0
Sell count0
Hold count2
Buy count5
Strong Buy count7
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 44.72%
- FII
- 10.72%
- MF
- 31.15%
- Other
- 13.41%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Freshers Walk-In Interview 2026 :Multiple Openings at Ipca Laboratories - BioTecNikaMarket news · 4 Jun 2026, 5:20 pm
Freshers Walk-In Interview 2026 :Multiple Openings at Ipca Laboratories BioTecNika
Ipca Laboratories Ltd gains for third straight session - Business StandardMarket news · 4 Jun 2026, 2:31 pm
Ipca Laboratories Ltd gains for third straight session Business Standard
Broad-Based Technical Strength Lifts Ipca Laboratories Ltd to 52-Week High of Rs 1662 - Markets MojoMarket news · 3 Jun 2026, 11:24 pm
Broad-Based Technical Strength Lifts Ipca Laboratories Ltd to 52-Week High of Rs 1662 Markets Mojo
Ipca Laboratories appoints Dr. Sandarbh Rishi as Head – MSAT/Pilot Plant - Indian Pharma PostMarket news · 3 Jun 2026, 6:30 pm
Ipca Laboratories appoints Dr. Sandarbh Rishi as Head – MSAT/Pilot Plant Indian Pharma Post
Ipca Laboratories Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals - Markets MojoMarket news · 3 Jun 2026, 1:05 pm
Ipca Laboratories Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals Markets Mojo
Ipca Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - Markets MojoMarket news · 3 Jun 2026, 8:05 am
Ipca Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals Markets Mojo
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.6.0000 per share(600%)Dividend
- board MeetingsAudited Results & Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for IPCA Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- IPCALAB
- BSE Code
- 524494
Questions
Stock FAQ
What is the symbol and ISIN of IPCA Laboratories?
IPCA Laboratories has the symbol IPCALAB and ISIN - INE571A01038.
What is the current price of IPCA Laboratories?
IPCA Laboratories is currently trading at INR 1,936.10.
What are the year high and year low of IPCA Laboratories?
IPCA Laboratories has a year high of INR 2,001.50 and a year low of INR 1,251.60.
What is the market capitalization of IPCA Laboratories?
IPCA Laboratories has a market capitalization of INR 43,877.97 crore.
What is the P/E ratio of IPCA Laboratories?
IPCA Laboratories has a P/E ratio of 35.60.
What is the dividend yield of IPCA Laboratories?
IPCA Laboratories has a dividend yield of 0.34%.
How is the financial performance of IPCA Laboratories based on revenue, net income, and EPS?
IPCA Laboratories has revenue of INR 9,646.33 crore, net income of INR 1,141.12 crore, and EPS of INR 47.46.
What is the book value of IPCA Laboratories?
IPCA Laboratories has a book value of INR 310.06.
What is the debt-to-equity ratio of IPCA Laboratories?
IPCA Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of IPCA Laboratories?
IPCA Laboratories has a price-to-book ratio of 6.24 and a price-to-sales ratio of 4.55.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.